Clinical Trial

De-Escalation Protocol Of HPV Mediated Oropharyngeal Squamous Cell Carcinoma

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 9, 2023 (before its estimated January 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the effects, good and/or bad, of treating participants with HPV-mediated oropharyngeal cancer, with less treatment, using the new staging system. The investigators believe this treatment will provide the same effectiveness as the usual treatment, but decrease the side effects. The radiation doses, chemotherapy doses, and the type of surgical approaches that will be used in this treatment protocol have all been previously investigated. Previous research suggests that this can be done safely, but there has not been a study done basing treatment on the new staging system.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2020-11-16; most recent amendment 2023-11-07.
Status change: Recruiting → Active, Not Recruiting 2023-11-07
Trial Details
NCT Number NCT04638465
Lead Sponsor Nebraska Methodist Health System
Conditions HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage, Oropharynx Cancer
Enrollment 150 participants
Start Date 2018-08-06
Primary Completion 2025-01 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2023-11-09